Stem cells, senescence, neosis and self-renewal in cancer

Cancer Cell International

Volumn 6, Issue , 2006, Pages

  Rajaraman, Rengaswami ^a   Guernsey, Duane L ^a   Rajaraman, Murali M ^a   Rajaraman, Selva R ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Downtown Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PACLITAXEL DERIVATIVE; PROTEIN P16INK4A; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANEUPLOIDY; ARTICLE; CANCER; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL AGING; CELL BUDDING; CELL DEATH; CELL DIVISION; CELL HETEROGENEITY; CELL MATURATION; CELL RENEWAL; CYTOKINESIS; CYTOLOGY; DAUGHTER CELL; EPIGENETICS; GENE ACTIVATION; GENE MUTATION; GENE REPLICATION; GENETIC CODE; GENOME; GENOTOXICITY; GIANT CELL; HUMAN; LIFESPAN; MITOSIS; MUTATIONAL ANALYSIS; NON HUMAN; ONCOGENE; PHENOTYPE; POLYPLOIDY; SOMATIC CELL; STEM CELL; TELOMERE; TUMOR SUPPRESSOR GENE;

EID: 33845299892     PISSN: 14752867     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-6-25     Document Type: Article

References (229)

1. Kliensmith LJ, Kish VM: Principles of cell and molecular biology. 2nd edition. Harper Collins College Publishers; 1996:517-561.
2. Hartwell LH: Defects in the cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992, 71:543-6.
3. Hartwell LH, Kasten MB: Cell cycle control and cancer. Science 1994, 266:1821-8.
4. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004, 73:39-85.
5. Sundaram M, Guernsey DL, Rajaraman MM, Rajaraman R: Neosis: A novel type of cell division in cancer. Cancer Biology & Therapy 2004, 3:207-218.
6. Rajaraman R, Rajaraman MM, Rajaraman SR, Guernsey DL: (2005). Neosis - A paradigm for self-renewal in cancer. Cell Biol International 2005, 29:1084-97.
7. Kennedy AR, Murphy G, Little JB: Effect of time and duration of exposure to 12-O-tetradeconoylphorbol-13-acetate on X-ray transformation of C3H10T1/2 cells. Cancer Res 1980, 40:1915-1920.
8. Reya T, Morriaon AJ, Clark MF, Weissman IL: Stem cells, Cancer and cancer stem cells. Nature 2001, 414:105-11.
9. Al-Haaj M, Wicha S, Benit-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. PNAS USA 2003, 100:3983-8.
10. Al-Haaj M, Becker MW, Wicha S, Weissman IL, Clarke MF: Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004, 14:43-7.
11. Al-Haaj M, Clarke MF: Self-renewal and solid tumor stem cells. Oncogene 2004, 23:7274-83.
12. Singh SK, Clarke ID, Takuichiro H, Dirks PB: Cancer stem cells to nervous system tumors. Oncogene 2004, 23:7267-74.
13. Yuan X, Curtin J, Xiong Y, Lin G, Waschssmann-Hogiu S, Farkas DL, et al.: isolation of caner stem cells fm adult glioblastoma multiforme. Oncogene 2004, 23:1-9.
14. Wicha MS, Liu S, Dontu G: Cancer Stem Cells: An Old Idea - A Paradigm Shift. Cancer Res 2006, 66:1883-1890.
15. Pardee AB: Role reversal for anti-cancer therapy. Cancer Biol Ther 2002, 1:426-7.
16. Chabner BA, Roberts TG Jr: Chemotherapy and the war on cancer. Nature reviews Cancer 2005, 5:65-72.
17. Gey GO, Coffman WD, Kubicek MT: Tissue culture studies of the growth properties of cervical carcinoma and normal epithelium. Cancer Res 1952, 12:264-65.
18. Hayflick L, Mooehead PS: The serial cultivation of human diploid cell stains. Exxp Cell Res 1961, 25:585-621.
19. Dimri GP: What has senescence got to do with cancer? Cancer Cell 2005, 7:505-512.
20. Castedo M, Perfettini J-L, Roomier T, Andreau K, Medema R, Kroemer G: Cell death by mitotic catastrophe; a molecular definition. Oncogene 2004, 23:2825-37.
21. Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-60.
22. Counter CM: The roles of telomere and telomerase in cell life span. Mat Res 1996, 366:45-63.
23. Hahn WC: Cancer: surviving on the edge. Cancer Cell 2004, 6:215-22.
24. D'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretski G, Carter NP, Jackson SP: A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198.
25. Takai H, Smogorzewska A, de Lange T: DNA damage foci at dysfunctional telomere. Curr Biol 2003, 13:1549-56.
26. Gire V, Roux P, Wynford-Thomas D, Brondello JM, Dulic V, et al.: DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J 2004, 23:2554-64.
27. Sell S: Stem cell origin of cancer and differentiaton therapy. Crit Rev Oncol Hematol 2004, 51:1-28.
28. Nomura T: An analysis of the changing urethan response of the developing mouse embryo in relation to mortality, malformation and neoplasm. Cancer Res 1974, 34:2217-31.
29. Wales JH, Sinnhuber RO, Hendricks JD, Nixon JB, Eisele TA: Afotoxin B1 induction of hepatocellular carcinoma in the embryos of rainbow trout (Salmo gairdieri). J Natl Cancer Inst 1978, 60:1133-9.
30. Kondo S: Resistance to cancer induction by carcinogens at early developmental stages and the latent period of induced neoplasms. In Phyletic Approahes to Cancer Edited by: Dawe CJ, Harshberger JC, Kondo S, Sigumura T, Takayama S. Tokyo, Japan Sci Spc Press; 1981:347-54.
31. Kondo S: Carcinogenesis in relation to the Stem Cell Mutation Hypothesis. Differentiation 1983, 24:1-8.
32. Park CH, Bergsagel DE, McCullach EA: Mouse myeloma tumor stem cells:a primary cell culture assay. J Natl Cancer Inst 1971, 46:411-22.
33. Till JE, McCullach EA: A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961, 14:213-22.
34. Pierce GB: Teratocarcinoma model for a developmental concept of cancer. Curr Top Dev Biol 1967, 2:223-46.
35. Cairns J: The origin of human cancers. Nature 1975, 255:197-200.
36. Perez-Lasoda J, Balmain A: Stem cell hierarchy in skin cancer. Nature Reviews Cancer 2002, 4:434-443.
37. Dick JE: Breast cancer stem cells revealed. Proc Natl Acad Sci USA 2003, 100:3547-3549.
38. Jordan CJ: Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol 2004, 16:708-12.
39. Michael D, Fojo T, Bates S: Tumor stem cells and drug resistance. Nature Rev Cancer 2005, 5:275-284.
40. Fang D, Nguyen TR, Leishear K, Finko R, Kulp AN, Hotz S, Von Belle PA, Xu X, Elder DE, Herlyn M: A tumorigenic subpopulation with stem cell properties In melanomas. Cancer Res 2005, 65:9328-37.
41. Collins AT, Berry PA, Hyde C, Stower, Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10945-51.
42. Hill RP: Identifying cancer stem cells in solid tumors: A case not proven. Cancer Res 2006, 66:1891-1896.
43. Vescovi AL, Galli R, Reynolds BA: Brain tumor stem cells. Nat Rev Cancer 2006, 6:425-436.
44. Editorial note, Nat Rev Cancer 2006, 6:415.
45. Wisemann A: Essays upon heredity and kindred biological problems Volume 1. Edited by: Poulton EB, Schonland S, Shipley AE. (Clarenden, Oxford); 1881:11-66.
46. Baird DT, Collins J, Egoscue J, Evem LH, et al.: Fertility and ageing. Hum Reprod Update 2005, 11:261-76.
47. Thomson JA, Ilskovitz-Eldor M, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al.: Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-7.
48. Nitaro R, Cimmino A, Tabari D, Rotoli B, Luzzatto L: In vivo telomerase dynamics of human hematopoietic stem cells. PNAS USA 1997, 94:13782-5.
49. Greenwood MJ, Lansdrop PM: Telomeres, telomerase, and hematopoietic stem cell biology. Arch Med Res 2003, 34:489-495.
50. Simonsen JL, Rosda C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG, Kassem M: Telomerase expression extends the prolifetative life-span and maintains the osteogenic potential of human bone marrow stromall cells. Nature Biotechnol 2002, 20:592-6.
51. Zimmerman S, Voss M, Kaiser S, Kapp U, Walker CV, Martens UM: Lack of telomerase activity in human mesenchymal stem cells. Leukemia 2003, 17:1146-9.
52. Keith WN: From stem cells to cancer. Balancing immortality and neoplasia. Oncogene 2004, 23:092-4.
53. Serakinci N, Gudberg P, Burns JS, Abdallah B, Schredder H, Jensen T, et al.: Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004, 23:5095-8.
54. Sarin KY, Cheung P, Gillson D, Lee E, Tennen RI, Wang E, Artandi MK, Oro AE, Artandi SE: Conditional telomerase induction causes proliferation of follicle stem cells. Nature 2005, 436:1048-52.
55. Gonzalez-Suarez E, Samper E, Ramirez A, Flores JM, Martin-Caballero J, Jorcano JL, Blasco MA: Increased epider mal tumors and increased skin woundhealing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J 2001, 20:2619-2630.
56. Pardee AB: A restriction point for control of normal animal cell proliferation. PNAS USA 1974, 71:1286-90.
57. Levy MS, Allsopp AC, Futcher AB, Greider CW, Harley CB: Tellomere end-replication problem and cell ageing. J Mol Biol 1992, 225:951-60.
58. Wright WE, Shay JW: The two stage mechanism controlling cellular senescence and immortalization. Exp Geront 1992, 27:83-9.
59. Wege H, Chui MS, Le HT, Strom SC, Zern MA: In vitro expansion of human heatocyytes is restricted by telomere-dependnt replicatiuve aging. Cell Transplant 2003, 12:897-906.
60. Wege H, Le HT, Chui MS, Lin L, Wu J, Giri R, Malhi H, Sappal BS, Kumaran V, Gupta S, Zern MA: Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology 2003, 124:432-444.
61. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al.: Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279:349-52.
62. Jun ES, Lee TH, Cho HH, Suh SY, Jung JS: Expression of telomerase extends longevity and enhances differentiation in human adipose tissue derived stromal cells. Cell Physiol Biochem 2004, 14:261-8.
63. Sharpless NE, DePinho RA: Telomeres, stem cells, senescence and cancer. J Clin Invest 2004, 39:175-9.
64. Allsopp RC, Morin GB, DePinho R, Harley CB, Weissman IL: Telomerase is required to slow telomere shortening and to extend replicative lifespan of HSCs during serial transplantation. Blood 2003, 102:517-520.
65. Dagarag M, Evazyan T, Rao N, Effros RB: Genetic manipulation of telomerase in HIV-specific CD8+ T cells: enhanced antiviral functions accompany the increased proliferative potential and telomere length stabilization. J Immunol 2004, 173:6303-6311.
66. Duesberg P, Fabarius A, Hehlmann R: Aneuploidy, the primary cause of multilateral genomic instability of neoplastic and preneoplastic cells. IUBMB Life 2004, 56:65-81.
67. Matzke MA, Mette MF, Kanno T, Matzke AJM: Does the intrinsic instability of aneuploid genomes hae a causal role in cancer? Trends Genet 2003, 19:253-6.
68. Nowell PC: The clonal evolution of tumor cell populations. Science 1976, 194:23-8.
69. Lapidot T: A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994, 367:645-8.
70. Reznikof CA, Bertram JS, Brankow DW, Heidelburger C: Quantitative and qualitative studies on chemical transformation of cloned C3H mouse embryo cells sensitive to post-confluence inhibition of cell division. Cancer Res 1973, 33:3239-3249.
71. Borek C: The induction and control of radiogenic transformation in vitro: cellular and molecular mechanisms. Pharmac Ther 1985, 27:99-142.
72. Heidelberger C, Freeman AE, Pienta RJ, Sivak A, Bertran JS, Castro BC, et al.: Cell transformation by chemical agents: a review and analysis of the literature. A report of the US Environmental Protection Agency Gene-Tox Program. Mutat Res 1983, 114:283-385.
73. LeBoeuf RA, Kerckaert GA, Aardema MA, Gibson DP, Brauninger R, Isfort RJ: The pH 6.7 Syrian hamster embryo cell transformation assay for assessing the carcinogenic potential of chemicals. Mutat Res 1996, 356:85-127.
74. Ambrose V: The functions of animal micoRNAs. Nature 2004, 431:350-5.
75. Bartel P: MicroRNAs: genomics, biogenesis, mechanism and function. Cell 2004, 116:281-97.
76. [http://www.cancerresearchuk.org/aboutcancer/whatiscancer/].
77. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al.: microRNA expression profiles classify human cancers. Nature 2005, 435:951-60.
78. Kuff DW, Pollack RE, Weicshallbaum RR, Bast RC Jr, Gansler TS, et al.: Cancer Medicine 6th edition. BC Decker Inc. Hamilton (Canada); 2003.
79. Smith JR, Pereira-Smith OM: Replicative senescence: implications for in vivo aging and tumor suppression. Science 1996, 273:63-67.
80. Campisi J: Cellular senescence as a tumor suppressor mechanism. Trends Cell Biol 2001, 11:527-31.
81. Campisi J: Suppressing cancer: the importance of being senescent. Science 2005, 309:886-7.
82. Narita M, Lowe SW: Senescence comes of age. Nature Medicine 2005, 11:920-922.
83. Braig M, Schmitt CA: Oncogene induced senescence; putting the breaks on Tumor Development. Cancer Res 2006, 66:2881-2884.
84. Roninson IB: Tumor cell senescence in cancer treatment. Cancer Research 2003, 63:2705-15.
85. Shay JW, Wright WE: Senescence and immortalization: Role of telomeres and Telomerase. Carcinogenesis 2005, 26:867-74.
86. Sherr CJ, DePinho R: Cellular senescence: mitotic clock or culture shock. Cell 2000, 102:407-10.
87. Serrano M, Lin AW, McCurrah ME, Beach D, Lowe SW: Oncogenic ras provokes cell senescence associated with accumulation of p53 and p161NK4A. Cell 1997, 88:593-602.
88. Freidberg EC: DNA damage and repair. Nature 2003, 421:436-40.
89. Makaravskiy AN, Siryapora E, Hixson DC, Akerley W: Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 2002, 59:1198-1211.
90. Weaver BAA, Cleveland DW: Decoding links between mitosis, cancer and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005, 8:7-12.
91. Schmitt CA: Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer 2003, 3:286-95.
92. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, et al.: Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:636-7.
93. Narita M, Narita M, Krizhanovsky V, Nunez S, Chicas A, Hearn SA, Myers MP, Lowe SW: A novel role for high-mobility group proteins in cellular senescence and heterochromatin formation. Cell 2006, 126:503-14.
94. Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D, et al.: Rb targets histone H3 methylation and HP1 to promotors. Nature 2001, 412:561-5.
95. Vandel L, Nicolas E, Vaute O, Ferreira R, Ait-Si-Ali S, Trouche D: Transcriptional repression by the retinoblastoma protein through the recruitment of a methyltransferase. Mol Cell Biol 2001, 21:6484-94.
96. Collado M, Gil J, Efeyan A, Guera C, Schumacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M: Senescence in premalignant tumours. Nature 2005, 436:642.
97. Chen Z, Trotman LC, Shaffer D, Lin H-K, Dotan ZA, Niki M, Kautcher JA, Scher hi, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
98. Denchi EL, Attwooll C, Pasini D, Helin K: Deregulated E2F activity induces hyperplasia and senescence-like features in mouse pituitary gland. Mol Cell Biol 2005, 25:2660-72.
99. Michaloglou C. Vredeveld LC, Soengas MS, Denovelle C, Kuilman T, van der Horst CM, et al.: BRAF600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:636-7.
100. Vogel H, Lim D-S, Karsenty G, Finegold M, Hasty P: Deletion of Ku86 causes early onset of senescence in mice. Proc Natl Acad Sci USA 1999, 96:10770-75.
101. McEachern MJ, Iyer S, Fulton TB, Blackburn EH: Telomere fusions caused by mutating terminal region of telomere DNA. PNAS USA 2000, 97:11409-11414.
102. Artandi SE, Chang S, Lee SL, Alison S, Gotlierb GJ, Chin L, DeOinho RA: Telomere dysfunction promotes non-reciprocal translocations and epithelial cvancers in mice. Nature 2000, 406:573-4.
103. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, Cawthon RM: Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA 2004, 101:17312-17315.
104. Lin AW, Barradas M, Stone JC, van Aeist L, Serrano M, Lowe SW: Premature senescence involving p53 and p16 is activated in response to MEK/MAPK mitogenic signaling. Genes Dev 1998, 12:3008-19.
105. Zhu J, Woods D, McMahon M, Bishop JM: Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998, 2:2997-3007.
106. Vousden K: Activation of p53 tumor suppressor protein. Biochim Biophys Acta 2002, 1602:47-59.
107. Garkavtsev I, Riabowol K: Extension of replicative life span of human diploid fibroblasts by inhibition of the p331NGI candidate tumor suppressor. Mol Cell Biol 1997, 17:2014-19.
108. Berdardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, pandolfi PP: PML regulates p53 stability by sequestering Mdm2 to the nucleus. Nat Cell Biol 2004, 6:665-72.
109. Ferbeyre G, de Stanchina E, Queido E, Baptiste N, Prives C, Lowe SW: PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 2000, 14:2015-27.
110. Langley E, Pearson M, Faretta M, Bauer U-M, Frye RA, et al.: Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 2002, 21:2383-96.
111. Colombo E, Marine JC, Danovi D, Falini B, Pelcci PG: Nucleoplasmin regulates the stability an transcriptional activity of p53. Nat Cell Biol 2002, 4:529-33.
112. Peeper DS, Dannenberg JH, Douma S, te Riele H, Bernards R: Escape from premature senescence is not sufficient for oncogenic tranaformation by Ras. Nature Cell Biol 2001, 3:198-203.
113. Zhang H, Herbert BS, Pan KH, Shay JW, Cohen SN: Disparate effects of telomere attrition on gene expression during replicative senescence of human mammary epithelial cells cultured under different conditions. Oncogene 2004, 19:6193-8.
114. Ben-Porath I, Weinberg RA: When cells get stressed:an integrative view of cellular senescence. J Clin Invest 2004, 113:8-13.
115. Ben-Porath I, Weinberg RA: The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005, 37:961-76.
116. Itahana K, Campisi J, Dimri GP: Mechanisms of cellular senescence in human and mouse cells. Biogerontology 2004, 5:1-10.
117. Shay JW, Roninson IB: Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004, 23:2919-33.
118. te Poele RH, Okorokov AL, Jardine L, Cunningham J, Josi BP: DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002, 62:1876-83.
119. Krtolica A, Parrinello S, Locket S, Desprez PY, Campisi J: Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging. PNAS USA 2001, 98:12072-77.
120. Boveri T: The origin of malignant tumors. In Translated by Marcella Boveri Baltimore: Williams & Wilkins; 1929.
121. Zitcer EM, Dunnabecke TH: Transformation ofcells from normal human amnion into established strains. Cancer Res 1957, 17:1047-53.
122. Zybina EV, Kudriavtseva MV, Kudriavtsev BN: Polyploidization and endomitosis in giant cells of rabbit trophoblast. Cell Tissue Res 1974, 160:525-37.
123. Zybina EV, Kudriavtseva MV, Kudriavtsev BN: Distribution of chromosome material during division of giant nuclei by fragmentation in rodent trophoblast. Morphologic and cytophotometric study. Tsitologia 1979, 21:12-20.
124. Cheung AN: Pathology of gestational trophoblast diseases. Best Prac Res Clin Obstet GynAcol 2003, 17:849-60.
125. Soundararajan R, Rao AJ: Trophoblast 'pseudo-tumorigenesis': Significance and contributory factors. Reproductive Biol and Endocinol 2004, 2:15-32.
126. Solari F, Domenget C, Gire V, Woods C, Lazarides E, Rousset B, et al.: Multinucleated cells can continuously generate mononcleated cells in the absence of mitosis: a study of the avian osteoclast lineage. J Cell Sci 1965, 108:3233-41.
127. Walen KH: The origin of transformed cells. Studiess on spontaneous and induced transformation in cell cultures from marsupials, a snail and human amniocytes. Cancer Genet Cytogenet 2002, 133:45-54.
128. Walen KH: Spontaneous cell transformation: Karyoplasts derived from multinucleate cells produce new cell growth from senescent human epithelial cell cultures. In Vitro Cell Dev Biol Animal 2004, 40:150-8.
129. Walen KH: Budded karyoplasts from multinucleated fibroblast cells contain centrosomes and change their morphology to mitotic cells. Cell Biol Int 2005, 29:1057-65.
130. Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, Tlsty TD: Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 2001, 409:633-7.
131. Roninson IB, Broude EV, Chong B-D: If not apoptosis then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updates 2001, 4:303-313.
132. Buikis I, Harju L, Freivalds T: Origin of microcells in human sarcoma cell line HT1080. Anal Cell Pathol 1999, 18:73-85.
133. Erenpreisa JA, Cragg MS, Fringes B, Sharakhov I, Illidge TM: Release of mitotic descendents by giant cells from Burkitt's lymphoma cell line. Cell Bio Iint 2000.
134. Erenpreisa J, Ivanov A, Cragg M, Selivanova G, illidge T: Nuclear envelope limted chromatin sheets are part of mitotic death. Histochem Cell Biol 2002, 117:243-55.
135. Erenpreisa J, Kalejs M, Ianzani F, Kosmacek EA, Mackey MA, Emzinzh D, Cragg MS, Ivanov A, Illidge TM: Segregation of genomes in polyploid tumor cells following mitotic catastrophe. Cell Bio Iint 2005, 29:1005-011.
136. Illidge TM, Cragg MS, Fringes B, Olive P, Erenpreisa JA: Polyploid giant cells provide a survival mechanism for mutant p53 cells after DNA damage. Cell Biol Int 2000, 24:621-33.
137. Shelton DN, Chang E, Whittier PS, Choi D, Funk WD: Microarray analysis of replicative senescence. Curr Biol 1999, 9:939-45.
138. Roberson RS, Kussick SJ, Valliers E, Chen S-YJ, Wu DU: Escape from therapy-induced accelerated cellular senescence in p3-null lung cancer cells and human lung cancers. Cancer Res 2005, 65:2795-803.
139. Kim NW, Piatyszek MA, Prowse Kr, Harley CB, West MD, Ho PL, et al.: Specific association of human telomerase activity in immortal cells and cancer. Science 1994, 266:2011-15.
140. Counter CM, Hirte HW, Bacchetti S, Harley CB: Telomerase activity in human ovarian carcinoma. PNAS USA 1994, 91:2900-4.
141. Meyerson M, Counter CM, Eaton EN, Ellison EW, Steiner P, Caddle SE, et al.: hEST2, the putative human telomerase subunit gene, is upregulated in tumor cells and immotalization. Cell 1998, 90:785-95.
142. [http://www.medicine.dal.ca/rajaraman].
143. Murray AW: Recycling the cell cycle: cyclins revisited. Cell 2004, 116:221-34.
144. Chabner BA, Roberets TG Jr: Chemotherapy and the war on cancer. Nat Rev Cancer 2005, 5:65-72.
145. Hartwell LH, Weinert TA: Checkpoint: controls that ensure the order of cell cycle events. Science 1989, 241:317-22.
146. Kops GJ, Foltz D, Cleveland DW: Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. PNAS USA 2004, 101:8699-8704.
147. Eaker S, Cobb J, Pyle A, Handel MA: Meiotic prophase abnormalities and metaphase cell death in MLH1 deficient mouse spermatocytes Insight into regulation of spermatogenic progress. Dev Biol 2000, 249:85-95.
148. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999, 401:616-620.
149. Nitta M, Kobayashi O, Honda S, Hirota T, Kuninaka S, Marumota T, et al.: Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene 2004, 23:6548-58.
150. Fingert HJ, Chang JD, Pardee AB: Cytotoxic, cell cycle and chromosomal effects of methylxanthines treated with alkylating agents. Cancer Res 1986, 46:2463-67.
151. Dewey WC, Ling CC, Myen RE: Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys 1995, 33:781-96.
152. Ivanov A, Cragg MS, Erenpreisa J, Emzinsh D, Likmn H, Illidge TM: Endopolyploid cells produced after severe genetic damage have the potential to repair DNA double strand breaks. J Cell Sci 2003, 116:4095-106.
153. Erenpreisa J, Kalejs M, Cragg MS: Mitotic catastrophe and endomitosis: An evolutionary key to a molecular solution. Cell Biol Int 2005, 29:1112-8.
154. Borel F, Lohez OD, Laeroix FB, Margolis RL: Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells. Proc Natl Acad Sci USA 2002, 99:9819-9824.
155. Andreassen PR, Lacroix FB, Lohez OD, Margolis RL: Neither p21WAFInor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAFI induces stable G1 arrest in resulting tetraploid cells. Cancer Res 2001, 61:7660-8.
156. Margolis RL: Tetraploidy and tumor development. Cancer Cell 2005, 8:353-4.
157. Qiu j: Epigenetics: the unfinished symphony. Nature 2006, 441:143-5.
158. McClintock B: The significance of genome's responses to challenge. Science 1984, 226:792-801.
159. Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-63.
160. Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genetics 2006, 7:21-33.
161. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006, 6:107-116.
162. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genetics 1999, 21:163-7.
163. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genetcs 2002, 3:415-28.
164. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, et al.: Epigenetic differences arise during the lifetime of monozygotic twins. PNAS USA 2005, 102:10604-9.
165. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. New Eng J Med 2003, 349:2042-54.
166. Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosome instability and tumors promoted by DNA hypermethylation. Science 2003:300, 455.
167. Holm TM, Jackson-grusby L, Brambrink T, Yamada Y, Rideout WM 3rd, Jaenisch R: Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 2005, 8:275-85.
168. Nishigaki M, Aovagi K, Danjo I, Fukaya M, Yanagihara K, Sakamoto M, et al.: Discovery of aberrant expression of R-RAS by cancer-linked hypomethylation in gastric cancer using microarrays. Cancer Res 2005, 65:2115-24.
169. Oshimo Y, Kuraoka K, Nakayama H, Kitadai Y, Yoshida K, Chayama K, Yasui W: Promoter methylation of cyclin D2 gene 1 n gastric carcinoma. Int J Oncol 2003, 23:1663-70.
170. Akiyama Y, Maesawa C, Ogasawara S, Terashima M, Masuda T: T celltype specifc repression of the mapsin gene is disrupted frequently in gastric intestinal metaplasia and cancer cels. Am J Pathol 2003, 165:1911-19.
171. Old LJ: Cancer/Testes (CT) antigens - a new link between gametogenesis and cancer. Cancer Immunol 2001, 1:1.
172. Tachibana K, Tanaka D, Isobe T, Kishimoto T: c-Mos forces the mitotic cell cycle to undergo meiosis II to produce haploid gametes. PNAS USA 2000, 97:14301-7.
173. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testes antigens, gametogenesis and cancer. Nat Rev Cancer 2005, 5:615-625.
174. Sagata N: What does Mos do in oocytes and somatic cells? Bioessays 1997, 19:13.
175. Kalejs M, Ivanov A, Plakhins G, Cragg MS, Emzinsh D, Illidge TM, Erenpreisa J: Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. Cancer 2006:6-15.
176. Dong CK, Masutomi K, Hahn WC: Telomerase regulation, function and transformation. Crit Rev Oncol Hematol 2005, 54:85-93.
177. Gonzalo S, Jaco I, Fraga MF, Chen T, Li E, Esteller M, Blasco MA: DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol 2006, 8:416-24.
178. Fukasawa K, Vande Woude GF: Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol 1997, 17:506-18.
179. Weinberg RA: Oncogenes, anti-oncogenes and the molecular basis of multistep carcinogenesis. Cancer Res 1989, 49:3713-21.
180. Mihich E, Hartwell L: Eight annual Pezcoller symposium: genomic instability and immortality in cancer. Cancer Res 1997, 57:4437-41.
181. Passegue E, Jamieson CH, Ailles LE, Weissman IL: Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reaquisition of stem cell characteristics. PNAS USA 2003, 100(S1):11842-9.
182. Chambers I, Smith A: Self-renewal 1 n teratocarcinoma and embryonic stem cells. Oncogene 2004, 34:7150-60.
183. Brener RH, Snijders PJ, Smit EF, Sutedja TG, Sewalt RG, Ott AP, et al.: increased expression f EZH2 polycomb group gene in BM11 positiveneoplastic cells during bronchial carcinogenesis. Neoplasia 2004, 6:736-43.
184. Clark AT, Rodrigues RT, Bodnar MS, Abeyta MJ, Cedars MI, Turek Pj, et al.: Human STELLAR, NANOG, and CDF3 genes are expressed in pluripotent cells and map to 12p13, a hotspot for teratocarcinoma. Stem Cells 2004, 22:169-79.
185. Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A: ABCG2 - a transporter for all seasons. FEBS Lett 2004, 567:116-20.
186. Dean M, Folo T, Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-84.
187. Erenpreisa J, Kalejs M, Ianani F, Kosmaek EA, Maackay MA, Cragg MS, et al.: Segregatioin of genomes in polyploid tumor cells following mitotic catastrophe. Cell Bio Iint 2005, 9:1005-11.
188. Dey P: Aneuploidly and malignancy: An unsolved equation. J Clin Pathol 2004, 57:1245-1249.
189. Hanesmann D: Uber asymmetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung. Arch Pathol Anat Physiol Klin Medicin 1890, 119:299-366.
190. Hardy PA, Zacharias H: A reappraisal of the Hansemann-Boveri hypothesis on the origin of tumors. Cell Biol Int 2005, 29:983-982.
191. Martin GM, Sprague CA: Parasexual cycle in cultivated human somatic cells. Science 1969, 166:761-3.
192. Terzi M, Hawkins TSC: Chromosomal variation and the establishment of somatic cell lines in vitro. Nature 1974, 253:361-2.
193. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 1994, 78:539-542.
194. Stewenius Y, Gorunova L, Jonson T, Larsson N, Hoglund M, Mandahi N, Mertons F, Mitelm Sn F, Gisselsson D: Structural and numerical chromosome changes in colon cancer develop through telomere-mediated anaphase bridges, not through mitotic multipolarity. Proc Natl Acad Sci USA 2005, 102:5541-5546.
195. Hassold T, Abruzzo M, Adkins K, Griffin D, merit M, Millie E, et al.: Human aneuploidly: incidence, origin and etiology, Environ. Environ Mol Mutagen 1996, 28:167-75.
196. Kops GJ, Weaver BA, Cleveland DW: On the road to cancer: aneuploidy and mitotic checkpoint. Nat Rev Cancer 2005, 5:773-85.
197. Shi Q, King RL: Chromosome non-disjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 2005, 437:1038-1042.
198. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D: Cytokinesis failure generating tetraploids promote tumorigenesis in p53-null cells. Nature 2005, 437:1043-1047.
199. Bunz F, Fauth C, Splecher MR, Dutriauch A, Sedivy JM, Kinzler Kw, et al.: Targeted inactivation of p53 in human cells does not result in aneuploidly. Cancer Res 2002, 62:1129-33.
200. Huang X, Tran T, Zhan L, Hatcher R, Zhang P: DNA damageinduced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. PNAS USA 2005, 102:1065-70.
201. Shackney SE, Smith CA, Miller BW, Burhot DR, Murtha K, Giles HR, et al.: Model for the genetic evolution of human solid tumors. Cancer Res 1989, 49:3344-54.
202. Ornitz DM, Hammer RE, Messing A, Palmitter RA, Brinster RL: Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science 1987, 238:188-93.
203. Heselmeyer K, Hellstrom Ac, Blegen H, Schrock E, Silfversward C, Shah K, et al.: Primary carcinoma of the fallopian tube: comparative genomic hybridization reveals high genetic instability and a specific, recurring pattern of chromosomal aberrations. Int J Gynecol Pathol 1998, 17:245-54.
204. Cross SM, Sanchez CA, Morgan CA, Schimke MA, Ramel S, Idzerda RL, et al.: p53-dependent mouse spindle checkpoint. Science 1995, 267:1353-6.
205. Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W, et al.: MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001, 409:355-359.
206. Baroja A, De La Hoz C, Alvarez A, Vielba R, Sarret R, Arechaga J, de Guadarias JM: Polyploidization and exit from cell cycle as mechanisms cultured melanoma cells resistance to methotrexate. Life Sci 1998, 62:2275-82.
207. Therman E, Sario GE, Kuhn EM: The course of endomitosis in human cells. Cancer Gen Cytogen 1986, 19:302-320.
208. Storchova Z, Pellman D: From polyploidy to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol 2004, 3:207-218.
209. Quintyne SJ, Reing JE, Hoffelder DR, Gollin SM, Saunders Ws: Spindle multipolarity is prevented by centrosomal clustering. Science 2005, 307:127-9.
210. Chang B-D, Braude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, Roninson IB: A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999, 59:3761-3767.
211. Nemoto S, Finkel T: Ageing and the mystery at Aries. Nature 2004, 429:149-52.
212. Grotewiel MS, Martin I, Bhandari P, Cook-Wiens E: Functional senescence in Drosophila melanogaster. Ageing Res Rev 2005, 4:372-97.
213. Vijg J, Suh Y: Genetics of longevity and ageing. Annual Rev Med 2005, 56:193-212.
214. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD: Altered cell cyxle and arrest and gene amplification potential accompany loss of wild type p53. Cell 1992, 70:605-20.
215. Yeager TR, DeVries S, Jarrad DF, Kao C, Nakada SY, Moon TD, Bruskewitz R, Stadler WM, Meisner LF, Gilchrist KW, Newton MA, Walter FM, Reznikoff CA: Overcoming cellular senescence in human cancer pathology. Genes and Development 1998, 12:163-174.
216. Ivanov A, Cragg MS, Erenpreisa J, Emzinsh D, Likmn H, Illidge TM: Endopolyploid cells produced after severe genetic damage have the potential to repair DNA double strand breaks. J Cell Sci 2003, 116:4095-106.
217. Nozaki T, Masutani M, Watanabe M, Ochiya T, Hasegawa F, Nakagama H, Suzuki H, Sugimura T: Syncytiotrophoblastic giant cells in teratocarcinoma-like tumors derived from Parp-disrupted mouse embryonic stem cells. Proc NAtl acad Sci USA 1999, 96:13345-50.
218. Kinzler KW, Vogelstein B: Lesons from hereditary colorectal cancer. Cell 1996, 87:159-170.
219. Kinzler KW, Vogelstein B: Cancer susceptibility genes. Gatekeepers and caretakers. Nature 1997, 386:761-763.
220. Vogelstein B, Lowe D, Levine AJ: Surfing the p53 network. Nature 2000, 408:307-310.
221. Vogelstein B, Kinzier KW: Cancer genes and the pathways they control. Nat Med 2004, 10:789-99.
222. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
223. [http://patient.cancerconsultants.com/centers.aspx?tierID= 827&linkID=].
224. Nardi V, Azam M, Daley GO: Mechanisms and implications of imatinib resistance mtations in BCR-ABL. Curr Opin Hematolo 2004, 11:35-43.
225. Azam M, Daley GO: Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm. Mol Diagn Ther 2006, 10:67-76.
226. Lyons SK, Clarke AR: Apoptosis and carcinogenesis. Br Med Bull 1997, 53:554-69.
227. Zlmonjic D, Brooks MW, Popescu N, Weinberg RA, Hahn WC: Derivation of human tumor cells in vitro without widespread genomic instability. Cancer Res 2001, 61:8838-44.
228. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-91.
229. Zhang H, Herbert PS, Pan KH, Shay JW, Cohen SN: Disparate effects of telomere attrition on gene expression during replicative senescence of human mammary epithelial cells cultured under different conditions. Oncogenes 2004, 19:6193-8.